Secukinumab, a novel anti-IL-17A antibody, can be quantified in skin after a single dose by dermal open flow microperfusion (dOFM)

被引：0
|
作者：
Bruin, G.
Dragatin, C.
Aigner, B.
Polus, F.
Calonder, C.
Froeliger, C.
Tiffner, K.
Bodenlenz, M.
Mader, J.
Korsatko, S.
Ratzer, R.
Pieber, T. R.
Loesche, C.
Sinner, F.
机构：
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2014年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 11 条
  • [1] Absolute levels of the novel anti-IL-17A antibody, secukinumab, in skin can be quantified by dermal open flow microperfusion (dOFM)
    Bruin, G.
    Dragatin, C.
    Aigner, B.
    Polus, F.
    Calonder, C.
    Froeliger, C.
    Tiffner, K.
    Bodenlenz, M.
    Mader, J.
    Korsatko, S.
    Ratzer, M.
    Pieber, T. R.
    Loesche, C.
    Sinner, F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S52 - S52
  • [2] Assessment of the immune response to novel Anti-IL-17A antibody, secukinumab, after intravenous and subcutaneous application in healthy subjects and patients
    Klein, U.
    Kolbinger, F.
    Liang, E.
    Vogel, B.
    Bruin, G.
    Lloyd, P.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 134 - 134
  • [3] IMMUNOGENICITY OF THE NOVEL ANTI-IL-17A ANTIBODY, SECUKINUMAB, WITH INTRAVENOUS AND SUBCUTANEOUS DOSING REGIMENS IN HEALTHY SUBJECTS AND PATIENTS
    Klein, U.
    Liang, E.
    Vogel, B.
    Kolbinger, F.
    Bruin, G.
    Lloyd, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 630 - 630
  • [4] β-defensin-2 (BD-2) responds to a single dose of anti-IL-17A secukinumab in different skin layers of psoriatic patients within days
    Loesche, C.
    Kolbinger, F.
    Valentin, M. -A.
    Jarvis, P.
    Cheng, Y.
    Bruin, G.
    Polus, F.
    Aigner, B.
    Bodenlenz, M.
    Sinner, F.
    Pieber, T. R.
    Patel, D. D.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 : 37 - 38
  • [5] Dermal open flow microperfusion (dOFM) to monitor local tissue response after dupilumab treatment in lesional and non-lesional skin of atopic dermatitis patients
    Tiffner, K.
    Ehall, B.
    Eberl, A.
    Bodenlenz, M.
    Pircher, T.
    Birngruber, T.
    Sinner, F.
    Pieber, T.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S348 - S348
  • [6] Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in subjects with moderate to severe plaque psoriasis
    Reich, Kristian
    Blauvelt, Andrew
    Armstrong, April
    Fox, Todd
    Huang, Jiaqing
    Bruin, Gerard
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S15 - S15
  • [7] Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
    Karle, Anette
    Spindeldreher, Sebastian
    Kolbinger, Frank
    MABS, 2016, 8 (03) : 536 - 550
  • [8] The anti IL-17A IgG1 antibody distributes in dermal interstitial fluid as demonstrated by using dermal open flow microperfusion after a single 300 mg subcutaneous administration; assessment in healthy volunteers and patients with moderate-to-severe plaque psoriasis
    Bruin, G.
    Dragatin, C.
    Aigner, B.
    Polus, F.
    Calonder, C.
    Froeliger, C.
    Tiffner, K.
    Bodenlenz, M.
    Mader, J.
    Korsatko, S.
    Ratzer, M.
    Pieber, T.
    Loesche, C.
    Sinner, F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S18 - S18
  • [9] Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis
    Gordon, Kenneth
    Leonardi, Craig
    Braun, Daniel
    Cameron, Gregory
    Erickson, Janelle
    Lebwohl, Mark
    Heffernan, Michael
    Banerjee, Subhashis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB183 - AB183
  • [10] Secukinumab exploratory study to investigate distribution in dermal interstitial fluid using dermal open flow microperfusion after single 300-mg subcutaneous administration: Pharmacokinetic assessment in healthy volunteers and patients with moderate to severe plaque-type psoriasis
    Bruin, Gerard
    Loesche, Christian
    Calonder, Claudio
    Polus, Florine
    Sinner, Frank
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB187 - AB187
12